CD8A and neoplasm: Meanwhile, the potential of combining I-DXd with PD-1 inhibition warrants exploration in clinical settings, as preliminary evidence suggests this combination can enhance CD8 + T cell recruitment, tumor suppression, and overall survival outcomes.